Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Complication and Response Assessment of High-Dose-Rate Endorectal Brachytherapy Boost in Neo-Adjuvant Chemoradiotherapy of Locally Advanced Rectal Cancer With Long-Term Outcomes Publisher



Saeedian A1, 2 ; Lashkari M1, 2 ; Ghalehtaki R1, 2 ; Taherioun M1, 2 ; Razmkhah M1, 2 ; Kazemian A1, 2 ; Aghili M1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Radiation Oncology, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Contemporary Brachytherapy Published:2023


Abstract

Purpose: To identify efficacy, complication, and pathologic response of high-dose-rate endorectal brachytherapy (HDR-BRT) boost in neo-adjuvant chemoradiotherapy (nCRT) of locally advanced rectal cancer. Material and methods: Forty-four patients who met eligibility criteria were included in this non-randomized comparative study. Control group was recruited retrospectively. nCRT (50.40 Gy/28 fr. plus capecitabine 825 mg/m2 twice daily) was administered to both groups before surgery. In the case group, HDR-BRT (8 Gy/2 fr.) was supplemented after chemoradiation. Surgery was done 6-8 weeks after completion of neo-adjuvant therapy. Pathologic complete response (pCR) was the study’s primary endpoint. Results: From 44 patients in the case and control groups, pCR was 11 (50%) and 8 (36.4%), respectively (p = 0.27). According to Ryan’s grading system, tumor regression grade (TRG) TRG1, TRG2, and TRG3 were 16 (72.7%), 2 (9.1%), and 4 (18.2%) in the case, and 10 (45.5%), 7 (31.8%), and 5 (22.7%) in the control group (p = 0.118). T down-staging was found in 19 (86.4%) and 13 (59.1%) patients in the case and control groups, respectively. No grade > 2 toxicity was identified in both the groups. Organ preservation was achieved in 42.8% and 15.3% in the case and control arm (p = 0.192). In the case group, 8-year overall survival (OS) and disease-free survival (DFS) were 89% (95% CI: 73-100%) and 78% (95% CI: 58-98%), respectively. Our study did not reach median OS and median DFS. Conclusions: Treatment schedule was well-tolerated, and neo-adjuvant HDR-BRT could achieve better T down-staging as a boost comparing with nCRT, without significant complication. However, the optimal dose and fractions in the context of HDR-BRT boost needs further studies. © 2023 Termedia Publishing House Ltd.. All rights reserved.
Related Docs
Experts (# of related papers)